
Taking a closer look at the Most Favored Nation Pricing Executive Order
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
This publication highlights industry-specific factors to be considered and provides guidance on the most pertinent accounting solutions for the pharmaceutical, life sciences and medical device industry.
Explore how pharma and biotech leaders can navigate FDA disruption with smarter submissions, regulatory agility, and global risk mitigation strategies.
Explore the rise of China’s biotech industry and what it means for U.S. pharma, from innovation and partnerships to diligence and global strategy.
Learn how hospitals can use reimbursement solutions for uncompensated care through Medicare bad debt reimbursement and hospital cost report strategies.
The FDA is facing major disruption. Clinical timelines and pipeline investments may be at risk. Discover four key actions US pharma can take now to stay ahead.
China’s biotech boom presents US pharma with both opportunity and risk. Biopharma leaders must reassess diligence, strategy and geopolitical exposure.
Explore how shifting policies, tariffs, AI, and regulatory changes are reshaping healthcare strategy, innovation, and affordability in 2025.
Learn how health plans can turn provider data management into a strategic advantage — improving compliance, reducing costs, and enhancing patient experience.
Discover how APPs can help health systems address workforce gaps, reduce costs and improve care.
With the right digital strategy, payers can build trusted relationships with members while promoting preventive, proactive and personalized care.
A deep dive on recent policy such as MFN prescription drug pricing, tariffs, anti-corruption enforcement and more.